The conversation discusses concerns about the effectiveness of RU58841 due to high temperatures during delivery. A user reassures that the heat will not affect its efficacy.
Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.
The post discusses potential links between low vitamin D levels and hair loss, and how correcting this might impact the effectiveness of Minoxidil and Finasteride treatments. The responses vary, with some suggesting that vitamin D deficiency would cause overall scalp hair loss, while others believe it would first affect the most sensitive areas.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.
The conversation discusses using 0.5mg Dutasteride once a week for hair loss, with suggestions to increase frequency for better results. The user plans to reassess the need for a hair transplant in six months and is concerned about potential side effects like gynecomastia.
KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.
A 23-year-old is using 0.25mg Finasteride for hair loss and experiencing increased shedding after initial reduction. Advice given is to wait longer for results, as hair cycles take time to adjust, and consider increasing the dose if no improvement occurs in a few months.
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.